Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 5, 2015 -- Oxford Immunotec Global PLC , a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT .CMV and T-SPOT.PRT products.

http://ift.tt/1DhEFGH